H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia (MTVA) with a Buy rating and $12 price target The firm says Metavia offers a “compelling opportunity” in the metabolic disease space based on its two “differentiated” pipeline programs.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA:
- MetaVia Inc. Reports Q2 2025 Financial Results and Strategic Progress
- Optimistic Buy Rating for MetaVia Driven by Promising Obesity Drug Developments and Strategic Collaborations
- MetaVia Highlights Clinical Trials and Future Plans
- MetaVia Extends Phase 1 Trial for Obesity Drug
- MetaVia extends Phase 1 clinical trial of DA-1726